Real-World Effectiveness and Safety of Tucatinib, Trastuzumab, and Capecitabine in HER2-Positive Advanced Breast Cancer: A Multicenter Portuguese Study

Objective: The HER2CLIMB trial demonstrated the benefit of tucatinib, trastuzumab and capecitabine (TTC) in human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer (ABC). However, it predated the clinical use of trastuzumab deruxtecan (T-DXd), leaving limited evidence for TTC...

Cijeli opis

Bibliografski detalji

Glavni autori:	Rita Quaresma Ferreira, Carolina Brandão Monteiro, Ana Catarina Dias, Francisca Abreu, Bogdana Darmits, Maria João Oura, Inês Ângelo, Joana Cabral, Alice Figueiredo, Ricardo Ferreira, Diogo Alpuim Costa, Maria Teresa Marques, Tiago Pina-Cabral, Filipe Araújo, Sandra Bento, Catarina Lopes Fernandes, Mariana Santiago, Bruno Silva, Maria Alexandra Montenegro, Diana Cardoso Simão, Leonor Fernandes, Sónia Duarte Oliveira
Format:	Artigo
Jezik:	Inglês
Izdano:	Galenos Publishing House 2026-07-01
Serija:	European Journal of Breast Health
Teme:	breast cancer her2 protein tucatinib real-world data survival analysis
Online pristup:	https://www.eurjbreasthealth.com/articles/real-world-effectiveness-and-safety-of-tucatinib-trastuzumab-and-capecitabine-in-her2-positive-advanced-breast-cancer-a-multicenter-portuguese-study/doi/ejbh.galenos.2026.2026-2-3
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!